Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?

[1]  Lang Yi,et al.  CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. , 2016, Biochimica et biophysica acta.

[2]  David Cyranoski,et al.  CRISPR gene-editing tested in a person for the first time , 2016, Nature.

[3]  A. Sood,et al.  RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. , 2016, Cancer treatment reviews.

[4]  David Cyranoski,et al.  Chinese scientists to pioneer first human CRISPR trial , 2016, Nature.

[5]  Hideaki Takahashi,et al.  JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma , 2016, Journal of experimental & clinical cancer research : CR.

[6]  Lucy F. Stead,et al.  Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq , 2015, Oncotarget.

[7]  Sita J. Saunders,et al.  An updated evolutionary classification of CRISPR–Cas systems , 2015, Nature Reviews Microbiology.

[8]  Zhiyao He,et al.  CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy. , 2015, Human gene therapy.

[9]  D. Peer,et al.  Nanomedicine as an emerging platform for metastatic lung cancer therapy , 2015, Cancer and Metastasis Reviews.

[10]  J. García-Foncillas,et al.  The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. , 2015, Oral oncology.

[11]  Wei-Hua Chen,et al.  Nanoparticle delivery of HIF1α siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. , 2015, Cancer letters.

[12]  Qing Yao,et al.  Amphiphilic poly(amino acid) based micelles applied to drug delivery: the in vitro and in vivo challenges and the corresponding potential strategies. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[13]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[14]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[15]  Kevin P. White,et al.  Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.

[16]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[17]  K. Harrington,et al.  Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial , 2014, Trials.

[18]  Stefano C. Meliga,et al.  CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojection array. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[19]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[20]  Mu-Kuan Chen,et al.  High Level of Plasma Matrix Metalloproteinase-11 Is Associated with Clinicopathological Characteristics in Patients with Oral Squamous Cell Carcinoma , 2014, PloS one.

[21]  Giuseppe Battaglia,et al.  Novel aspects of encapsulation and delivery using polymersomes. , 2014, Current opinion in pharmacology.

[22]  Yoshimitsu Takahashi,et al.  In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. , 2014, Biochemical and biophysical research communications.

[23]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[24]  Nicholas A Peppas,et al.  Therapeutic applications of hydrogels in oral drug delivery , 2014, Expert opinion on drug delivery.

[25]  A. Sosnik.  Alginate Particles as Platform for Drug Delivery by the Oral Route: State-of-the-Art , 2014, ISRN pharmaceutics.

[26]  G. Laurent,et al.  Involvement of CD74 in head and neck squamous cell carcinomas , 2014, Journal of Cancer Research and Clinical Oncology.

[27]  Jeffry D. Sander,et al.  CRISPR-Cas systems for editing, regulating and targeting genomes , 2014, Nature Biotechnology.

[28]  E. Tajara,et al.  Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models , 2014, Molecular Cancer.

[29]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[30]  G. Rettig,et al.  Knockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  P. Harari,et al.  Enhanced radiation sensitivity in HPV-positive head and neck cancer. , 2013, Cancer research.

[32]  T. Shirakawa,et al.  Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines , 2013, Acta oto-laryngologica.

[33]  Christopher H Contag,et al.  Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[34]  V. Mishra,et al.  Receptor-based targeting of therapeutics. , 2013, Therapeutic delivery.

[35]  Eugene V Koonin,et al.  CRISPR-Cas , 2013, RNA biology.

[36]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[37]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[38]  Seung Woo Cho,et al.  Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease , 2013, Nature Biotechnology.

[39]  Linda Lavery,et al.  Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. , 2012, Cancer research.

[40]  S. H. van der Burg,et al.  Therapy of human papillomavirus-related disease. , 2012, Vaccine.

[41]  Zibin Gao,et al.  Nanotechnology applied to overcome tumor drug resistance. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Won Jong Kim,et al.  Bioreducible polymers for gene silencing and delivery. , 2012, Accounts of chemical research.

[43]  Mark E. Davis,et al.  Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[44]  D. Leake,et al.  Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. , 2012, Human Gene Therapy.

[45]  S. Chong,et al.  Poly-L-arginine and Dextran Sulfate-Based Nanocomplex for Epidermal Growth Factor Receptor (EGFR) siRNA Delivery: Its Application for Head and Neck Cancer Treatment , 2012, Pharmaceutical Research.

[46]  Y. Oh,et al.  Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. , 2011, Biomaterials.

[47]  S. Wu,et al.  Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[48]  N. Johnson,et al.  Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology. , 2011, Periodontology 2000.

[49]  I. Frazer,et al.  Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[50]  T. Ramqvist,et al.  An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention. , 2011, Anticancer research.

[51]  Eva Maria Hoffmann,et al.  Advances in orodispersible films for drug delivery , 2011, Expert opinion on drug delivery.

[52]  Dan Peer,et al.  The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. , 2010, Biomaterials.

[53]  Aliasgar Shahiwala,et al.  Medicated chewing gum – a potential drug delivery system , 2010, Expert opinion on drug delivery.

[54]  Hiroshi Maeda,et al.  Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. , 2010, Bioconjugate chemistry.

[55]  C. Van Waes,et al.  CK2 Modulation of NF-κB, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 Oligonucleotides In vitro or In vivo via Sub–50-nm Nanocapsules , 2010, Clinical Cancer Research.

[56]  W. Jiskoot,et al.  Transcutaneous Immunization Studies in Mice Using Diphtheria Toxoid-Loaded Vesicle Formulations and a Microneedle Array , 2010, Pharmaceutical Research.

[57]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[58]  L. Seymour,et al.  Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma , 2009, Cancer Gene Therapy.

[59]  S. Sen,et al.  Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma , 2009, Head & neck.

[60]  K. Engels,et al.  Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin , 2009, International journal of cancer.

[61]  P. Coursaget,et al.  Inhibition of cervical cancer cell growth by human papillomavirus virus–like particles packaged with human papillomavirus oncoprotein short hairpin RNAs , 2009, Molecular Cancer Therapeutics.

[62]  M. Tong,et al.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF , 2008, Journal of cellular biochemistry.

[63]  N. Muñoz,et al.  Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. , 2008, Vaccine.

[64]  Z. Tao,et al.  Effect of blocking VEGF, hTERT and Bcl-xl by multiple shRNA expression vectors on the human laryngeal squamous carcinoma xenograft in nude mice , 2008, Cancer biology & therapy.

[65]  J. Grandis,et al.  NF-κB Gene Signatures and p53 Mutations in Head and Neck Squamous Cell Carcinoma , 2007, Clinical Cancer Research.

[66]  P. Dervan,et al.  Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. , 2007, ACS chemical biology.

[67]  J. Gilbert,et al.  Systemic and global toxicities of head and neck treatment , 2007, Expert review of anticancer therapy.

[68]  Ibtissem Grissa,et al.  The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats , 2007, BMC Bioinformatics.

[69]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[70]  Marc-André Elsliger,et al.  Rare cancer-specific mutations in PIK3CA show gain of function , 2007, Proceedings of the National Academy of Sciences.

[71]  J. Minna,et al.  Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells , 2007, Reproductive Sciences.

[72]  C. Van Waes,et al.  Nuclear factor-κB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101 , 2007, Molecular Cancer Therapeutics.

[73]  W. Gu,et al.  Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes , 2006, Cancer Gene Therapy.

[74]  S. Merajver,et al.  Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. , 2006, Cancer research.

[75]  Takeshi Ono,et al.  Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5‐fluorouracil and docetaxel in head and neck squamous cell carcinoma , 2006, Cancer science.

[76]  Yingjie Zhang,et al.  Engineering mucosal RNA interference in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[77]  Takahiro Ochiya,et al.  Therapeutic potential of RNA interference against cancer , 2006, Cancer science.

[78]  M. Ozsahin,et al.  The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications , 2006, Radiation oncology.

[79]  J. Mattick,et al.  Non-coding RNA. , 2006, Human molecular genetics.

[80]  N. Grishin,et al.  A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action , 2006, Biology Direct.

[81]  Anastasia Khvorova,et al.  3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets , 2006, Nature Methods.

[82]  W. Duan,et al.  Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[83]  M. Kizaki,et al.  Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA , 2006, Cancer Gene Therapy.

[84]  B. Gabrielli,et al.  RNA Interference against Human Papillomavirus Oncogenes in Cervical Cancer Cells Results in Increased Sensitivity to Cisplatin , 2005, Molecular Pharmacology.

[85]  S. Salzberg,et al.  The Transcriptional Landscape of the Mammalian Genome , 2005, Science.

[86]  Robert E. Brown,et al.  Nuclear Factor-kappaB Pathway as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma: Pharmaceutical and Molecular Validation in Human Cell Lines Using Velcade and siRNA/NF-κB. , 2005 .

[87]  P. Celec,et al.  Vectors and delivery systems in gene therapy. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[88]  K. Taira,et al.  Induction of DNA methylation and gene silencing by short interfering RNAs in human cells , 2004, Nature.

[89]  K. Morris,et al.  Small Interfering RNA-Induced Transcriptional Gene Silencing in Human Cells , 2004, Science.

[90]  E. Sontheimer,et al.  Distinct Roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA Silencing Pathways , 2004, Cell.

[91]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[92]  P. Friedlander,et al.  Efficacy of transfection rates on head and neck squamous cell cancer by a novel adenovirus: An in vivo and in vitro study , 2002, Head & neck.

[93]  J. Milner,et al.  Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference , 2002, Oncogene.

[94]  A. Asokan,et al.  Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. , 2002, Journal of pharmaceutical sciences.

[95]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[96]  D. Sidransky,et al.  Head and neck cancer. , 2001, The New England journal of medicine.

[97]  J. Mattick.  Non‐coding RNAs: the architects of eukaryotic complexity , 2001, EMBO reports.

[98]  G. Hannon,et al.  C . elegans involved in developmental timing in Dicer functions in RNA interference and in synthesis of small RNA , 2001 .

[99]  A. Caudy,et al.  Argonaute2, a Link Between Genetic and Biochemical Analyses of RNAi , 2001, Science.

[100]  P. Ratcliffe,et al.  Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.

[101]  S. Davis,et al.  Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[102]  T. Tuschl,et al.  RNA interference is mediated by 21- and 22-nucleotide RNAs. , 2001, Genes & development.

[103]  L. Portugal,et al.  Salvage treatment for recurrent squamous cell carcinoma of the oral cavity , 2000, Head & neck.

[104]  D. Trono,et al.  Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery , 1998, Journal of Virology.

[105]  E J Topol,et al.  Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.

[106]  H. Farhood,et al.  The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. , 1995, Biochimica et biophysica acta.

[107]  Leaf Huang,et al.  Nanoparticle Delivered VEGF-A siRNA Enhances Photodynamic Therapy for Head and Neck Cancer Treatment. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[108]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[109]  A. Jimeno,et al.  Molecular pathways in head and neck cancer: EGFR, PI3K, and more. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[110]  R. Mulherkar,et al.  Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma. , 2012, Anticancer research.

[111]  A. Singhania,et al.  Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models , 2011, Gene Therapy.

[112]  Ruud H. Brakenhoff,et al.  The molecular biology of head and neck cancer , 2011, Nature Reviews Cancer.

[113]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[114]  J. Grandis,et al.  NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[115]  T. Watts,et al.  Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium , 2007, BDJ.

[116]  Z. Tao,et al.  [Inhibitory effect of silencing hTERT gene by short hairpin RNA on growth of human laryngeal squamous cell carcinoma xenograft in nude mice]. , 2006, Ai zheng = Aizheng = Chinese journal of cancer.

[117]  M. Kay,et al.  Adeno-associated virus vectors for short hairpin RNA expression. , 2005, Methods in enzymology.

[118]  Robert E. Brown,et al.  Nuclear Factor-kappaB Pathway as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma : Pharmaceutical and Molecular Validation in Human Cell Lines Using Velcade and siRNA / NF-κ , 2005 .

[119]  James A. Birchler,et al.  RNAi-mediated pathways in the nucleus , 2005, Nature Reviews Genetics.

[120]  N K Jain,et al.  Pegnology: a review of PEG-ylated systems. , 2002, Die Pharmazie.